News

Job markets today are transforming rapidly. In the past few years, we have experienced a paradigmatic shift in the way we work, with the creation of entirely new industries and roles created, along with many jobs being phased out...

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

Takeda Pharmaceutical from Japan said on December 17, 2025, that its experimental pill for a type of skin disease, which is developed using artificial intelligence, has succeeded in two late-stage studies. Over half of the plaque psoriasis patients throughout the...

Egypt has gone on to mark quite a prominent milestone when it comes to its biopharmaceutical development by laying the foundation stone for the GENNVAX vaccine manufacturing facility, which is all set to become the largest fully integrated vaccine...

For a $950 million upfront, Sobi is all set to get rights to pozdeutinurad - oral URAT1 inhibitor that performed pretty well in the Phase II studies. Sobi is taking over Arthrosi Therapeutics, which is California-based, in a move to...